Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Douglas Prevost

Orthopaedic Surgery Anchorage, AK Medical Doctor

NPI 1952376022 CMS profile 315690

4100 Lake Otis Pkwy Ste 108, Anchorage, AK 99508

Open in the dashboard

General payments

$4,880

50 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Douglas Prevost of Anchorage, AK is reported in the CMS Open Payments database as having received $4,880 across 50 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,808 13
2024 General $35 1
2023 General $504 7
2022 General $1,718 14
2021 General $680 11
2020 General $101 2
2019 General $34 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Douglas Prevost
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Douglas Prevost were reported at $1,808. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Douglas Prevost Orthopaedic Surgery median Middle half National median
2019 $34 $644 $140–$2,844 $163
2020 $101 $312 $75–$1,860 $114
2021 $680 $520 $117–$2,495 $132
2022 $1,718 $598 $128–$2,731 $149
2023 $504 $461 $128–$2,264 $160
2024 $35 $497 $134–$2,475 $164
2025 $1,808 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. DePuy Synthes Sales Inc. $1,901 7 payments
  2. Stryker Corporation $1,749 15 payments
  3. Medical Device Business Services, Inc. $729 13 payments
  4. Ethicon US, LLC $101 3 payments
  5. Arthrex, Inc. $86 1 payment
  6. Heron Therapeutics, Inc. $66 1 payment
  7. Alaska Medical Technologies, LLC $54 1 payment
  8. Acumed LLC $43 1 payment
  9. Smith+Nephew, Inc. $39 2 payments
  10. Ferring Pharmaceuticals Inc. $33 2 payments
  11. Other $79 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,102 8 payments
  2. Food and Beverage $1,778 42 payments
Products named General payments · program years 2019–2025
  1. MAKO $1,574 11 payments
  2. Velys $460 3 payments
  3. ACTIS $106 3 payments
  4. ATTUNE Ortho-Knee $93 3 payments
  5. ATTUNE Ortho-Knee $66 1 payment
  6. CORAIL $66 1 payment
  7. ZYNRELEF $66 1 payment
  8. STRATAFIX $53 2 payments
  9. AXSOS Non-Locking Plate $49 1 payment
  10. AXSOS Locking Plates $48 1 payment
  11. Other $441 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 92 billing codes

Paid by Medicare

$460,943

Of which drugs: $42,821

Medicare patients

583

Average age 72

Services billed

11,420

373 women, 210 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 65%
Ischemic heart disease 22%
Diabetes 21%
Depression 18%
Osteoporosis 15%
Atrial fibrillation 12%
Chronic kidney disease 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 66 100 $40,395
Injection, methylprednisolone acetate, 1 mg J1010 Office 80 8,841 $899
Injection, methylprednisolone acetate, 80 mg J1040 Office 34 47 $345

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

50 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Alaska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record